Ascenion, technology transfer partner of Hannover Medical School (MHH), has supported the conclusion of a collaboration and licence agreement between MHH and Novo Nordisk.

This year’s BioVaria is digital and takes place exclusively online from the 26 to 28 April 2021.

As part of its ‘GO-Bio initial’ programme, the BMBF has awarded Ascenion funding for its 'Life Science Digital Hub' concept to improve support for GO-Bio initial applicants.

We would like to thank all our clients, colleagues and partners in technology transfer, research and industry for the enjoyable and productive…

Ascenion’s portfolio company HepaRegeniX achieves an important preclinical milestone indicating beneficial therapeutic effects of its lead candidate in certain liver carcinomas.

An innovative approach to combat infections caused by Staphylococcus aureus will receive funding of initially 1.33 million USD plus an additional 7.44 million USD, depending on project progress. It is jointly developed by the HZI and the LDC.

Ascenion will support eight members and four partners of the Innovative Training Network (ITN) ‘SMABEYOND’ in all aspects relating to the intellectual property and potential commercialization of their work.

Ascenion’s portfolio company iThera gained regulatory approval for a pivotal trial evaluating its MSOT imaging technology for the assessment of colon inflammation. If successful, it could provide a superior, non-invasive alternative to colonoscopy.

How is the German start-up sector doing? Are there ‘zombies’ here too – as in the USA? And what should we be looking out for? A number of heads of German technology transfer organisations were interviewed for this overview, including Ascenion’s Christian Stein.

Supporting start-ups has always been a particular focus of our activities. In 2019, we have seen significant successes and opposing trends in this area. Here our summary of highlights, figures and key developments in the start-up field and beyond.

The TransferAllianz proposes 5 measures to leverage the innovation potential of academic research and drive sustainable economic recovery following the corona crisis.

BERLIN, 28 August 2020 – Aignostics, a spin-off from Charité - Universitätsmedizin Berlin and the Berlin Institute of Health (BIH) pioneering…

• T-knife’s proprietary humanized mouse platform (HuTCR) T-cell Receptors expected to provide superior affinity/specificity properties
• Series A round led by Versant Ventures and RA Capital Management, with strong participation from seed investors Andera Partners and BIVF

HepaRegeniX has demonstrated proof-of-efficacy in acute liver disease in preclinical studies performed in collaboration with the University Hospital of Tübingen (Germany) and the Mayo Clinic (Rochester, MN, USA).

Ankara, Turkey

Cologne, Germany

Munich, Germany

Kiel, Germany